Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justus Duyster

Showing results (11-20 of 248) with videos related to

Pageof 25
Sort By:
Experimental Hematology|September 25, 2007
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutationsRama Krishna Kancha, Rebekka Grundler, Christian Peschel, et al.
Lancet (London, England)|February 21, 2002
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective studyNikolas von Bubnoff, Folker Schneller, Christian Peschel, et al.
Journal of Cellular and Molecular Medicine|February 18, 2010
Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapyUlrich Keller, Nikolas von Bubnoff, Christian Peschel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapyRama Krishna Kancha, Nikolas von Bubnoff, Christian Peschel, et al.
Molecular and Cellular Biology|January 26, 2002
Role for the adaptor protein Grb10 in the activation of AktThomas Jahn, Petra Seipel, Susanne Urschel, et al.
Blood|February 19, 2005
FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation modelRebekka Grundler, Cornelius Miething, Christian Thiede, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2013
Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatmentRobert C Bauer, Jana Sänger, Christian Peschel, et al.
Blood|June 7, 2006
The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)Nikolas von Bubnoff, Sivahari Prasad Gorantla, Silvia Thöne, et al.
Annals of Hematology|December 17, 2013
Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosisHelga Maurer, Peter Haas, Tobias Wengenmayer, et al.
Cell Cycle (Georgetown, Tex.)|March 2, 2005
A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatmentNikolas von Bubnoff, Simone Barwisch, Michael R Speicher, et al.
Pageof 25

Showing results (11-20 of 248) with videos related to

Sort By:
Pageof 25
Experimental Hematology|September 25, 2007
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutationsRama Krishna Kancha, Rebekka Grundler, Christian Peschel, et al.
Lancet (London, England)|February 21, 2002
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective studyNikolas von Bubnoff, Folker Schneller, Christian Peschel, et al.
Journal of Cellular and Molecular Medicine|February 18, 2010
Oncologist's/haematologist's view on the roles of pathologists for molecular targeted cancer therapyUlrich Keller, Nikolas von Bubnoff, Christian Peschel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapyRama Krishna Kancha, Nikolas von Bubnoff, Christian Peschel, et al.
Molecular and Cellular Biology|January 26, 2002
Role for the adaptor protein Grb10 in the activation of AktThomas Jahn, Petra Seipel, Susanne Urschel, et al.
Blood|February 19, 2005
FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation modelRebekka Grundler, Cornelius Miething, Christian Thiede, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2013
Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatmentRobert C Bauer, Jana Sänger, Christian Peschel, et al.
Blood|June 7, 2006
The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)Nikolas von Bubnoff, Sivahari Prasad Gorantla, Silvia Thöne, et al.
Annals of Hematology|December 17, 2013
Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosisHelga Maurer, Peter Haas, Tobias Wengenmayer, et al.
Cell Cycle (Georgetown, Tex.)|March 2, 2005
A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatmentNikolas von Bubnoff, Simone Barwisch, Michael R Speicher, et al.
Pageof 25